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Abstract
Aims: To describe the utility and safety of intravascular lithotripsy (IVL) in the setting
of primary percutaneous coronary intervention (PCI) for ST elevation myocardial
infarction (STEMI).
Methods and results: We performed a retrospective analysis, across six UK sites of
all patients in whom IVL was used for coronary calcium modification of the culprit
lesion during primary PCI for STEMI. The 72 patients were included. IVL was used in
de-novo culprit lesions in 57 (79%) of cases and culprit in-stent restenoses in
11 (15%) of cases. In four cases (6%) it was used in a newly deployed stent when this
was under-expanded due to inadequate calcium modification. Of the 30 cases in
which intracoronary imaging was available for stent analysis, the average stent
expansion was 104%. Intra-procedural stent thrombosis occurred in one case (1%),
and no-reflow in three cases (4%). The 30 day MACE rates were 18%.
Conclusion: IVL appears to be feasible and safe for use in the treatment of calcific
coronary artery disease in the setting of STEMI.
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1 | INTRODUCTION
Primary PCI is increasingly performed in older and more co-morbid
patients,1,2 with more calcified and complex coronary artery disease.
Angiographic coronary artery calcium (CAC) is frequent in target
lesions in STEMI,3 associated with worsened epicardial flow, a poorer
response to fibrinolytic therapy, and is an independent risk factor for
increased cardiovascular major adverse events (MACE).4
Existing tools for calcium modification have limitations in STEMI
whichmay restrict their use. Repeated high pressure balloon dilatation in a
thrombotic lesion can cause distal embolization. Although data are scarce
on the use of rotational atherectomy in STEMI, it is relatively contra-
indicated due to the risk of no-reflow caused by embolization of athero-
matous debris. This risk is likely to be greater in the highly thrombotic
milieu of STEMI, where the microvasculature may already be congested.
There is also a risk of increased platelet activation by the heat generated
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by the rapidly rotating burr. Perhaps as a consequence, the use of rota-
tional atherectomy is low in non ST elevation myocardial infarction
(NSTEMI) and STEMI- 0.7% in a pooled analysis of the HORIZONS-AMI
andACUITY trials.3
Coronary intravascular lithotripsy (IVL; Shockwave Medical, CA,
USA) is an emerging treatment modality for vascular calcium that may
offer advantages over existing therapies. IVL has been shown to be
safe and effective in patients with calcific disease requiring revascular-
ization for stable clinical syndromes.5
Coronary calcium is a major risk factor for stent underexpansion
and subsequent stent failure,3,6-8 In addition to facilitating optimal
stent expansion in de-novo lesions,5 IVL has demonstrated utility in
the management of under-expanded stents due to coronary
calcification,9 and may be of particular use in this subset of patients
presenting with STEMI. As a balloon-based therapy, IVL has a reduced
learning curve compared to other calcium modification techniques,
and with the potential for low complication rates, may have an advan-
tage over these existing tools..5
Here we present the first description of procedural characteristics
and safety outcomes following IVL use in STEMI.
2 | METHODS
2.1 | Study design and patient population
We performed a retrospective analysis of all patients in whom IVL
was used during primary PCI at six UK sites between June 2018 and
September 2020. Inclusion criteria were presentation fulfilling criteria
for STEMI (chest discomfort or other symptoms suggestive of ische-
mia and ST segment elevation in at least two contiguous ECG leads)
and the use of IVL in the culprit lesion during the primary PCI. All
patients received IVL as part of standard care, with therapy adminis-
tered as per the manufacturer's recommendations.
2.2 | Procedure
Interventional strategy was determined by anatomy and operator
preference. Antithrombotic therapy was prescribed according to cur-
rent guidelines.
2.3 | Endpoints
The primary safety endpoint was procedural complications and in-
hospital major adverse cardiac events (MACE), defined as all-cause
death, non-fatal myocardial infarction (MI) or target vessel revasculari-
zation (TVR).10
2.4 | Definitions
An undilated lesion was defined as a lesion which failed to yield
despite high pressure (>18 atm) inflation of a non-compliant
(NC) balloon sized 1:1 to the vessel. Severe angiographic calcification
was defined as radiopacities seen before contrast injection, appearing
to involve both sides of the arterial lumen on angiography. Concentric
calcium was defined as >270 calcium arc seen on intracoronary imag-
ing. Thrombolysis in Myocardial Infarction (TIMI) criteria was used to
describe coronary flow, and has been defined previously.11 No reflow
(TIMI 0–1) was defined as a persistent reduction in coronary flow in
the absence of dissection, spasm, stenosis or thrombus of the epicar-
dial vessel.12 Stent expansion was defined as the minimum stent area
(MSA) divided by the distal reference area, expressed as a percentage.
Stent underexpansion was defined as stent expansion <90%. Target
lesion revascularization (TLR) was defined as repeat percutaneous
intervention of the target lesion or bypass surgery of the target vessel
performed for restenosis or other complication of the target lesion.10
Bleeding was defined as BARC Type 3 bleeding.13 Significant
bystander lesions were defined as major epicardial arteries with >70%
angiographic stenosis.
2.5 | Statistical analysis
Continuous data are expressed as a mean ± SD, categorical data are
expressed as total number and percentage unless otherwise stated.
TABLE 1 Patient characteristics
All patients (n = 72)




Smoking (current/previous) 53% (38)
Renal impairmenta 36% (26)
Previous CABG 4%3
Previous PCI 25%15
Statin therapy 47% (34)
Warfarin/DOAC pre-admission 10%7
BMI, kg/m2 (SD) 26.3 (4.8)
LVEF<55% 72% (52)
LVEF<35% 29%16
Abbreviations: CABG, coronary artery bypass grafting; BMI, body mass
index; DOAC, direct oral anticoagulant; LVEF = left ventricular ejection
fraction; PCI, percutaneous coronary intervention.
aeGFR<60 ml/min.
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3 | RESULTS
We identified 72 eligible patients, over a 2 year period, representing
1% of total STEMI procedures undertaken across the six sites. The
total annual STEMI number of the sites is 3,328, the total annual num-
ber of PCIs 11,912, and the total annual number of IVL cases 503.
Patient characteristics are shown in Table 1.
Procedural characteristics are shown in Table 2. IVL was used
in de-novo culprit lesions in 57 (79%) of cases and culprit in-stent
restenoses in 11 (15%) of cases. In four cases (6%) it was used in
a newly deployed, under-expanded stent when this was due to
inadequate calcium modification. In 71% of cases, IVL was used




Time of day 8 a.m.–8 p.m. 68% (49)
8 p.m.–8 a.m. 32%17





Access radial 88% (63)








Onset to reperfusion time, min (SD) 272 (375)
LV support- IABP 4%3
Aspiration thrombectomy 8%6
GIIb/IIIa inhibitor 26%18













Calcium arc (degrees) (n = 29) 314











No. stents implanted, culprit lesion (SD) 1.8 (1.0)
Max stent diameter, culprit lesion, mm (SD) 3.5 (0.5)
Total stent length, culprit lesion, mm (SD) 56.4 (27)
Stent expansion (%) (n = 30) 104
Bystander disease None 43% (31)











DAPT  aspirin + ticagrelor 82% (59)
DAPT – aspirin + clopidogrel 5%4
Aspirin + DOAC/warfarin 3%2




Procedure time, min (SD) 99 (42)
Screening time, min (SD) 26 (12)
Abbreviations: CABG, coronary artery bypass grafting; DAPT, dual anti-
platelet therapy; DOAC, direct oral anti-coagulant; LMS, left main stem;
LAD, left anterior descending; LCX, left circumflex; RCA, right coronary
artery TIMI, thrombolysis in myocardial infarction; LV, left ventricle; IABP,
intra-aortic balloon pump; IVL, intravascular lithotripsy; NC, non-
compliant; IVUS, intravascular ultrasound; OCT, optical coherence
tomography; PCI, percutaneous coronary intervention.
TABLE 3 Outcomes
All patients (n = 72)




In-hospital death 11 (15%)
In-hospital stroke 3 (4%)
In-hospital TVR 0 (0%)
In-hospital bleeding 5 (7%)
30-day death 12 (17%)
30-day MI 1 (1%)
30-day TVR 1 (1%)
30-day MACE (death/MI/TVR) 18%
Abbreviations: VT, ventricular tachycardia; VF, ventricular fibrillation; TVR,
target lesion revascularization; MI, myocardial infarction; MACE, major
adverse cardiovascular events.
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after the culprit lesion failed to yield to high pressure NC balloon
inflation. In 21% of cases, IVL was used in an under-expanded
stent (whether a previously or newly placed). In 4%, IVL was used
prior to any other calcium modification, based on the presence of
concentric calcium seen on intracoronary imaging, and in 4%, the
operators elected to use IVL prior to any other calcium modifica-
tion, because severe calcification was identified on angiography.
Procedural and clinical outcomes are shown in Table 3. Intra-
procedural stent thrombosis occurred in one case (1%), and no-reflow
in three cases (4%), two of which occurred immediately after delivery
of IVL, in cases with TIMI 0–1 flow at the start of the case. The third
instance of no-reflow occurred in a patient with initially TIMI 3 flow,
following repeated high pressure inflations with an NC balloon (prior
to IVL). 30-day all-cause death occurred in 12 (17%) of patients. There
was one case of repeat infarction requiring TVR, due to stent throm-
bosis of an inadequately expanded stent (due to inadequate calcium
F IGURE 1 Coronary angiogram showing occluded left anterior
descending (LAD) (Black arrow) and calcification within the occluded
vessel (Red arrow) [Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 2 Coronary angiogram following PCI after calcium
modification with IVL
F IGURE 3 Intravascular ultrasound (IVUS) of the left anterior
descending (LAD), showing >270 arc of calcium
F IGURE 4 Intravascular ultrasound (IVUS) demonstrating calcium
fractures (Red arrows) following delivery of IVL [Color figure can be
viewed at wileyonlinelibrary.com]
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modification during the index procedure). Overall 30-day MACE rates
were 18%.
4 | DISCUSSION
This retrospective analysis describes the procedural characteris-
tics and safety outcomes in patients treated with IVL during
STEMI.
Although STEMI is most commonly caused by rupture of thin
capped lipid rich plaque, in 8% of STEMI the culprit lesion is an eroded
calcified nodule. As CAC increases with age,21 the incidence of calcifi-
cation (54%) within all STEMIs19 and eroded calcific nodules are also
likely to increase.
Dealing with CAC in the context of STEMI may carry a higher
risk of procedural complications and, if CAC is inadequately
treated, a higher risk of stent failure. Existing technologies such as
high pressure balloon inflation, scoring or cutting balloons and rota-
tional atherectomy are associated with increased rates of slow/no
reflow, severe dissection and perforation. This may translate to a
reluctance to modify calcium within STEMI and explain the low use
of these technologies. We hypothesize that these risks may be
reduced with IVL, due to the low pressure inflations used (4-6 atm)
and the absence of distal embolization of calcific remnants.14 Our
findings were consistent with this hypothesis and demonstrated
low rates of procedural complications or inpatient adverse events.
Rates of no-reflow were low (4%, compared to reported rates of
20–30%17,22) with no cases of perforation reported in keeping with
safety rates previously published for IVL.23 The low incidence of
no-reflow may reflect a lower need for repeated high pressure bal-
loon inflation to achieve lesion expansion.
Given the strong association of CAC with age and diabetes it is
not surprising that the patients described within this cohort were
older (73, compared to the average age of STEMI in the United King-
dom (UK)-63 for men, 72 for women within the UK registry2) and had
a high incidence of diabetes (22%, compared to 20.5% of men and
22.4% of women presenting with STEMI within the UK registry.2) In
total, 57% of patients in this cohort had significant bystander disease,
slightly higher than previously published rates of between 28 and
53% of multivessel disease in patients presenting with STEMI.15,18,24
IVL was used within the culprit lesion in all these patients,
and included in this were culprit lesions occurring in previously
placed stents (15%), and in cases in which the newly deployed
stent remained underexpanded despite high pressure post-
dilatation (6%). Overall, IVL was used for under-expanded stents
(whether newly placed or pre-existing) in 21% of cases, an indica-
tion which has previously been described.9 The threshold of
appropriate use for IVL remains poorly defined, within our series
high pressure NC balloons were used unsuccessfully in 76% of
cases prior to IVL.
Coronary angiography is insensitive for the diagnosis of CAC
which may explain the high incidence of intravascular imaging within
our cohort (55%, compared to 2.7% in a large US registry of all acute
myocardial infarctions, and compared to 9% in all PCI in the UK.
(20, 21)). Intravascular imaging is a sensitive way of identifying the
need for calcium modifying therapies and assessing both the response
to therapy and the final stent result. Of the 29 cases in which
intracoronary imaging was performed prior to IVL, there was an aver-
age calcium arc of 314, indicating appropriate use of IVL. One such
representative case is shown in Figures 1-5. A further potential advan-
tage of IVL is the ability to modify deep wall and / or medial coronary
calcium and thereby restore vessel compliance, this may in turn trans-
late into larger MSAs and a lower incidence of stent failure. Indeed, of
the 30 cases in which intracoronary imaging was available for stent
analysis, the average stent expansion was 104%, indicating satisfactory
mechanical results achieved in these heavily calcified lesions.
The majority of cases (68%) were performed between 8 a.m. and
8 p.m. Overnight, when priority is placed on performing shorter proce-
dures and the interventional team is smaller this may translate to a
reluctance to use adjunctive, particularly complex technology such as
rotational atherectomy. The short learning curve of IVL and relative
ease of use may circumnavigate this potential barrier.
Our findings were consistent and demonstrated low rates of pro-
cedural complications or inpatient adverse events related to the PCI.
Rates of no-reflow were low (4%, compared to reported rates of
20%–30%17,22) with no cases of perforation reported in keeping with
safety rates previously published for IVL.23 The low incidence of no-
reflow may reflect a lower need for repeated high pressure balloon
inflation to achieve lesion expansion.
The 30 day mortality rate of this cohort was 17%, significantly
higher than 30 day mortality rates for STEMI of 9% from both UK and
Swedish national registries.2,25 Of the 12 deaths, eight were cardiac
F IGURE 5 Intravascular ultrasound (IVUS) demonstrating
satisfactory stent expansion within the heavily calcified segment of
left anterior descending (LAD)
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deaths, and all due to cardiogenic shock or ventricular arrhythmia in
patients with severe LV impairment, most of whom were older than
80 years. The non-cardiac deaths included one due to hypoxic brain
injury complicating out of hospital arrest, two were due to malignancy
and one perforated cholecystitis.
Although this study is limited by the lack of control group and
modest sample size, it provides a “real-world” demonstration of the
utility and safety of IVL use in STEMI and adds to the growing body
of evidence of the important role of IVL in coronary calcium
modification.
5 | CONCLUSION
In the setting of primary PCI for STEMI, IVL appears to be a safe and
effective tool for modification of calcified coronary lesions prior to
stent implantation.
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